Kathleen Dorritie

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 410 citations · Full text

Medicine, Immunology, Oncology +17

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Tanya Siddiqi, David G. Maloney, Saad S. Kenderian et al. · The Lancet · 2023 · 198 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Michael Boyiadzis, Mounzer Agha, Robert L. Redner et al. · Cytotherapy · 2017 · 179 citations

Life Sciences, Immunology, Oncology +17

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Yucai Wang, Preetesh Jain, Frederick L. Locke et al. · Journal of Clinical Oncology · 2023 · 176 citations · Full text

Medicine, Hematology, Oncology +16

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie et al. · Blood · 2021 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +17